United States - English - NLM (National Library of Medicine)

physicians total care, inc. - cefdinir (unii: ci0fao63wc) (cefdinir - unii:ci0fao63wc) - cefdinir 300 mg - cefdinir capsules contain 300 mg cefdinir and the following inactive ingredients: carboxymethylcellulose calcium, colloidal silicon dioxide and magnesium stearate. the empty hard gelatin capsule shells contain fd&c blue #1, d&c red #28, titanium dioxide, gelatin and sodium lauryl sulphate. the capsules are printed with edible ink containing black iron oxide and shellac.

United States - English - NLM (National Library of Medicine)

a-s medication solutions - cefdinir (unii: ci0fao63wc) (cefdinir - unii:ci0fao63wc) - cefdinir 300 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir and other antibacterial drugs, cefdinir should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. cefdinir capsules are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. caused by haemophilus influenzae (including β-lactamase producing strains), haemophilus parainfluenzae (including β-lactamase producing strains), streptococcus pneumoniae (penicillin-susceptible strains only), and moraxella catarrhalis (including β-lactamase producing strains) (see clinical studies ).

United States - English - NLM (National Library of Medicine)

a-s medication solutions - cefdinir (unii: ci0fao63wc) (cefdinir - unii:ci0fao63wc) - cefdinir 300 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir and other antibacterial drugs, cefdinir should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. cefdinir capsules, usp are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. community-acquired pneumonia caused by haemophilus influenzae (including β-lactamase producing strains), haemophilus parainfluenzae (including β-lactamase producing strains), streptococcus pneumoniae (penicillin-susceptible strains only), and moraxella catarrhalis (including β-lactamase produci

United States - English - NLM (National Library of Medicine)

northwind pharmaceuticals, llc - cefdinir (unii: ci0fao63wc) (cefdinir - unii:ci0fao63wc) - cefdinir 300 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir and other antibacterial drugs, cefdinir should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. cefdinir capsules are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. adults and adolescents community-acquired pneumonia caused by haemophilusinfluenzae (including β-lactamase producing strains), haemophilusparainfluenzae (including β-lactamase producing strains), streptococcus pneumoniae (penicillin-susceptible strains only), and moraxella catarrhalis (including β-lactamase

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - cefdinir monohydrate (unii: 6e7sn358se) (cefdinir - unii:ci0fao63wc) - cefdinir 250 mg in 5 ml - to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir and other antibacterial drugs, cefdinir should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. cefdinir for oral suspension is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. adults and adolescents community-acquired pneumonia caused by haemophilus influenzae (including β-lactamase producing strains), haemophilus parainfluenzae (including β-lactamase producing strains), streptococcus pneumoniae (penicillin-susceptible strains only), and moraxella catarrhalis (inclu

United States - English - NLM (National Library of Medicine)

a-s medication solutions - cefdinir (unii: ci0fao63wc) (cefdinir - unii:ci0fao63wc) - cefdinir 250 mg in 5 ml - to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir and other antibacterial drugs, cefdinir should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. cefdinir for oral suspension is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. community-acquired pneumonia caused by haemophilus influenzae (including β-lactamase producing strains), haemophilus parainfluenzae (including β-lactamase producing strains), streptococcus pneumoniae (penicillin-susceptible strains only), and moraxella catarrhalis (including β-lactamase pr

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - cefdinir (unii: ci0fao63wc) (cefdinir - unii:ci0fao63wc) - to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir and other antibacterial drugs, cefdinir should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. cefdinir for oral suspension is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. adults and adolescents community-acquired pneumonia caused by haemophilus influenzae  (including β-lactamase producing strains), haemophilus parainfluenzae  (including β-lactamase producing strains), streptococcus pneumoniae  (penicillin-susceptible strains only), and moraxella catarrhalis  (including β-lactamase producing strains) (see clinical studies ). acute exacerbations of chronic bronchitis caused by haemophilus influenzae  (including β-lactamase producing strains), haemophilus parainfluenzae  (including β-lactamase producing strains), streptococcus pneumoniae  (penicillin-susceptible strains  only), and moraxella catarrhalis  (including β-lactamase producing strains). acute maxillary sinusitis caused by haemophilus influenzae  (including β-lactamase producing strains), streptococcus pneumoniae  (penicillin-susceptible strains only), and moraxella catarrhalis  (including β-lactamase producing strains). note:  for information on use in pediatric patients, see pediatric use  and dosage and administration . pharyngitis/tonsillitis caused by streptococcus pyogenes  (see clinical studies ). note:  cefdinir is effective in the eradication of s. pyogenes  from the oropharynx. cefdinir has not, however, been studied for the prevention of rheumatic fever following s. pyogenes  pharyngitis/tonsillitis. only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. uncomplicated skin and skin structure infections caused by staphylococcus aureus  (including β-lactamase producing strains) and streptococcus pyogenes . pediatric patients acute bacterial otitis media caused by haemophilus influenzae  (including β-lactamase producing strains), streptococcus pneumoniae  (penicillin-susceptible strains only), and moraxella catarrhalis  (including β-lactamase producing strains).pharyngitis/tonsillitis caused by streptococcus pyogenes  (see clinical studies ). note:  cefdinir is effective in the eradication of s. pyogenes  from the oropharynx. cefdinir has not, however, been studied for the prevention of rheumatic fever following s. pyogenes  pharyngitis/tonsillitis. only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. uncomplicated skin and skin structure infections caused by staphylococcus aureus  (including β-lactamase producing strains) and streptococcus pyogenes . cefdinir is contraindicated in patients with known allergy to the cephalosporin class of antibiotics.  

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - cefdinir (unii: ci0fao63wc) (cefdinir - unii:ci0fao63wc) - to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir and other antibacterial drugs, cefdinir should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. cefdinir for oral suspension is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. adults and adolescents community-acquired pneumonia caused by haemophilus influenzae  (including β-lactamase producing strains), haemophilus parainfluenzae  (including β-lactamase producing strains), streptococcus pneumoniae  (penicillin-susceptible strains only), and moraxella catarrhalis  (including β-lactamase producing strains) (see clinical studies ). acute exacerbations of chronic bronchitis caused by haemophilus influenzae  (including β-lactamase producing strains), haemophilus parainfluenzae  (including β-lactamase producing strains), streptococcus pneumoniae  (penicillin-susceptible strains  only), and moraxella catarrhalis  (including β-lactamase producing strains). acute maxillary sinusitis caused by haemophilus influenzae  (including β-lactamase producing strains), streptococcus pneumoniae  (penicillin-susceptible strains only), and moraxella catarrhalis  (including β-lactamase producing strains). note:  for information on use in pediatric patients, see pediatric use  and dosage and administration . pharyngitis/tonsillitis caused by streptococcus pyogenes  (see clinical studies ). note:  cefdinir is effective in the eradication of s. pyogenes  from the oropharynx. cefdinir has not, however, been studied for the prevention of rheumatic fever following s. pyogenes  pharyngitis/tonsillitis. only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. uncomplicated skin and skin structure infections caused by staphylococcus aureus  (including β-lactamase producing strains) and streptococcus pyogenes . pediatric patients acute bacterial otitis media caused by haemophilus influenzae  (including β-lactamase producing strains), streptococcus pneumoniae  (penicillin-susceptible strains only), and moraxella catarrhalis  (including β-lactamase producing strains).pharyngitis/tonsillitis caused by streptococcus pyogenes  (see clinical studies ). note:  cefdinir is effective in the eradication of s. pyogenes  from the oropharynx. cefdinir has not, however, been studied for the prevention of rheumatic fever following s. pyogenes  pharyngitis/tonsillitis. only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. uncomplicated skin and skin structure infections caused by staphylococcus aureus  (including β-lactamase producing strains) and streptococcus pyogenes . cefdinir is contraindicated in patients with known allergy to the cephalosporin class of antibiotics.  

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - cefdinir (unii: ci0fao63wc) (cefdinir - unii:ci0fao63wc) - to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir and other antibacterial drugs, cefdinir should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. cefdinir capsules, usp are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. community-acquired pneumonia caused by haemophilus influenzae (including β-lactamase producing strains), haemophilus parainfluenzae (including β-lactamase producing strains), streptococcus pneumoniae (penicillin-susceptible strains only), and moraxella catarrhalis (including β-lactamase producing strains) (see clinical studies ). acute exacerbations of chronic bronchitis caused by haemophilus influenzae (including β-lactamase producing strains), haemophilus parainfluenzae (including β-lactamase producing strains), streptococcus pneumoniae (penicillin-susceptible strains only), and moraxella catarrhalis (including β-lactamase producing strains). acute maxillary sinusitis caused by haemophilus influenzae (including β-lactamase producing strains), streptococcus pneumoniae (penicillin-susceptible strains only), and moraxella catarrhalis (including β-lactamase producing strains). note: for information on use in pediatric patients, see pediatric use   and dosage and administration . pharyngitis/tonsillitis caused by streptococcus pyogenes (see clinical studies ). note: cefdinir is effective in the eradication of s. pyogenes from the oropharynx. cefdinir has not, however, been studied for the prevention of rheumatic fever following s. pyogenes pharyngitis/tonsillitis. only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. uncomplicated skin and skin structure infections caused by staphylococcus aureus (including β-lactamase producing strains) and streptococcus pyogenes . acute bacterial otitis media caused by haemophilus influenzae (including β-lactamase producing strains), streptococcus pneumoniae (penicillin-susceptible strains only), and moraxella catarrhalis (including β-lactamase producing strains). pharyngitis/tonsillitis caused by streptococcus pyogenes (see clinical studies ). note: cefdinir is effective in the eradication of s. pyogenes from the oropharynx. cefdinir has not, however, been studied for the prevention of rheumatic fever following s. pyogenes pharyngitis/tonsillitis. only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. uncomplicated skin and skin structure infections caused by staphylococcus aureus (including β-lactamase producing strains) and streptococcus pyogenes . cefdinir capsules are contraindicated in patients with known allergy to the cephalosporin class of antibiotics.

United States - English - NLM (National Library of Medicine)

denton pharma, inc. dba northwind pharmaceuticals - cefdinir (unii: ci0fao63wc) (cefdinir - unii:ci0fao63wc) - to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir capsules and other antibacterial drugs, cefdinir capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. cefdinir capsules are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below.  caused by haemophilus influenzae (including β-lactamase producing strains), haemophilus parainfluenzae (including β-lactamase producing strains), streptococcus pneumoniae (penicillin-susceptible strains only), and morax